Carregant...
Overcoming delivery barriers in immunotherapy for glioblastoma
Glioblastoma is one of the deadliest forms of primary adult tumors, with median survival of 14.6 months post-diagnosis despite aggressive standard of care treatment. This grim prognosis for glioblastoma patients has changed little in the past two decades, necessitating novel treatment modalities. On...
Guardat en:
| Publicat a: | Drug Deliv Transl Res |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer US
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8164566/ https://ncbi.nlm.nih.gov/pubmed/34053034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13346-021-01008-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|